- Home
- NDLS vs FEMY Comparison
NDLS vs FEMY Comparison
Compare NDLS & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- FEMY
- Stock Information
- Founded
- NDLS 1995
- FEMY 2004
- Country
- NDLS United States
- FEMY United States
- Employees
- NDLS N/A
- FEMY N/A
- Industry
- NDLS Restaurants
- FEMY Medical/Dental Instruments
- Sector
- NDLS Consumer Discretionary
- FEMY Health Care
- Exchange
- NDLS Nasdaq
- FEMY Nasdaq
- Market Cap
- NDLS 32.9M
- FEMY 31.9M
- IPO Year
- NDLS 2013
- FEMY 2021
- Fundamental
- Price
- NDLS $0.90
- FEMY $0.91
- Analyst Decision
- NDLS Strong Buy
- FEMY Strong Buy
- Analyst Count
- NDLS 2
- FEMY 3
- Target Price
- NDLS $3.00
- FEMY $8.67
- AVG Volume (30 Days)
- NDLS 223.1K
- FEMY 280.4K
- Earning Date
- NDLS 08-06-2025
- FEMY 08-07-2025
- Dividend Yield
- NDLS N/A
- FEMY N/A
- EPS Growth
- NDLS N/A
- FEMY N/A
- EPS
- NDLS N/A
- FEMY N/A
- Revenue
- NDLS $495,670,000.00
- FEMY $1,699,232.00
- Revenue This Year
- NDLS $5.37
- FEMY $231.84
- Revenue Next Year
- NDLS $0.68
- FEMY $245.28
- P/E Ratio
- NDLS N/A
- FEMY N/A
- Revenue Growth
- NDLS N/A
- FEMY 61.97
- 52 Week Low
- NDLS $0.55
- FEMY $0.69
- 52 Week High
- NDLS $1.83
- FEMY $1.80
- Technical
- Relative Strength Index (RSI)
- NDLS 61.53
- FEMY 50.88
- Support Level
- NDLS $0.66
- FEMY $0.90
- Resistance Level
- NDLS $0.82
- FEMY $0.99
- Average True Range (ATR)
- NDLS 0.08
- FEMY 0.07
- MACD
- NDLS 0.02
- FEMY 0.01
- Stochastic Oscillator
- NDLS 93.68
- FEMY 39.48
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.